SequelSEC

Werewolf Therapeutics, Inc. HOWL

Pharmaceutical Preparations · CIK 0001785530 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2026-06-30
Operating income
$7.16M
Fiscal year ended 2026-06-30
Free cash flow
Unavailable
Fiscal year ended 2026-06-30

Werewolf Therapeutics, Inc. (HOWL) reported net income of $3.67M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from Werewolf Therapeutics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Werewolf Therapeutics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
RevenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income$7.16MUnavailable-$9.42M-$15.73MUnavailableUnavailable-$20.35M-$17.12MUnavailableUnavailable
Net income$3.67MUnavailable-$8.38M-$16.37MUnavailableUnavailable-$20.40M-$16.67MUnavailableUnavailable
Research & development$6.16MUnavailable$6.93M$11.63MUnavailableUnavailable$15.73M$12.53MUnavailableUnavailable
Weighted-average diluted sharesshares 48.60MUnavailableUnavailableshares 45.80MUnavailableUnavailableUnavailableshares 43.70MUnavailableUnavailable
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expenseUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Diluted EPS$0.08UnavailableUnavailable$-0.36UnavailableUnavailableUnavailable$-0.38UnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$7.68MUnavailable$2.48M$4.09MUnavailableUnavailable$4.62M$4.60MUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Werewolf Therapeutics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Cash & equivalents$21.99MUnavailable$57.05M$65.71MUnavailableUnavailable$111.00M$122.83MUnavailableUnavailable
Total assets$24.16MUnavailable$69.40M$79.63MUnavailableUnavailable$126.93M$140.04MUnavailableUnavailable
Current assets$22.89MUnavailable$58.59M$68.17MUnavailableUnavailable$113.07M$125.84MUnavailableUnavailable
Total liabilities$7.86MUnavailable$44.59M$50.01MUnavailableUnavailable$53.54M$50.66MUnavailableUnavailable
Current liabilities$7.86MUnavailable$36.15M$17.60MUnavailableUnavailable$15.18M$12.46MUnavailableUnavailable
Total equity incl. NCI$16.29MUnavailable$24.80M$29.61MUnavailableUnavailable$73.39M$89.38MUnavailableUnavailable
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailable$32.08M$32.08MUnavailableUnavailable$32.08M$32.08MUnavailableUnavailable
Accounts payable$1.94MUnavailable$754.00K$1.08MUnavailableUnavailable$3.04M$1.24MUnavailableUnavailable

Cash flow

Werewolf Therapeutics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Operating cash flow$6.63MUnavailable-$11.02M-$15.16MUnavailableUnavailable-$14.25M-$12.46MUnavailableUnavailable
Capital expendituresUnavailableUnavailable$0$0UnavailableUnavailable$123.00K$3.00KUnavailableUnavailable
Investing cash flowUnavailableUnavailable$0$0UnavailableUnavailable-$123.00K-$3.00KUnavailableUnavailable
Financing cash flowUnavailableUnavailable$2.37M$3.27MUnavailableUnavailable$2.55M-$6.00KUnavailableUnavailable
Net change in cash-$25.37MUnavailable-$8.66M-$11.88MUnavailableUnavailable-$11.83M-$12.47MUnavailableUnavailable
Stock-based compensation$419.00KUnavailable$1.21M$1.23MUnavailableUnavailable$1.91M$2.01MUnavailableUnavailable
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

Werewolf Therapeutics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Free cash flowUnavailableUnavailable-$11.02M-$15.16MUnavailableUnavailable-$14.38M-$12.46MUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio2.91xUnavailable1.62x3.87xUnavailableUnavailable7.45x10.10xUnavailableUnavailable
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailable1.08xUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open HOWL in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-07-31View SEC filing
10-Q · Filed 2026-05-07View SEC filing
10-K · Filed 2026-03-27View SEC filing
10-Q · Filed 2025-11-04View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-08View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Reconciliation checks needing review

14 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

gross profit bridgeinconsistent2026-03-31

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2026-03-31

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2025-06-30

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2025-06-30

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2025-03-31

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2025-03-31

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2024-06-30

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2024-06-30

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2024-03-31

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2024-03-31

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2023-06-30

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2023-06-30

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.